MRK Merck & Company, Inc. Common Stock (new)
Tentang Merck & Company, Inc. Common Stock (new) Tinjauan perusahaan dari Wikipedia
Merck & Co., Inc., berbisnis dengan nama Merck Sharp & Dohme (MSD) di luar Amerika Serikat dan Kanada, adalah sebuah perusahaan farmasi multinasional asal Amerika Serikat dan merupakan salah satu perusahaan farmasi terbesar di dunia. Merck didaftarkan sebagai sebuah badan hukum di New Jersey.
Baca selengkapnya
Merck & Co., Inc., berbisnis dengan nama Merck Sharp & Dohme (MSD) di luar Amerika Serikat dan Kanada, adalah sebuah perusahaan farmasi multinasional asal Amerika Serikat dan merupakan salah satu perusahaan farmasi terbesar di dunia. Merck didaftarkan sebagai sebuah badan hukum di New Jersey.
Pada tahun 1887, seorang pegawai Merck KGaA, Theodore Weicker, pergi ke Amerika Serikat untuk menjadi perwakilan Merck di sana. Pada tahun 1891, dengan modal sebesar $200.000 dari E. Merck, Weicker mendirikan Merck & Co, dengan kantor pusat di Manhattan. Pada tahun yang sama, George Merck, anak E. Merck yang masih berusia 23 tahun, bergabung dengan Weicker di New York. Merck & Co didirikan sebagai anak usaha Merck KGaA di Amerika Serikat. Merck & Co. lalu dirampas oleh pemerintah Amerika Serikat selama Perang Dunia I, sehingga Merck & Co dipisah menjadi sebuah perusahaan independen pada tahun 1917. Walaupun tetap beroperasi dengan nama Merck & Co. di Amerika Serikat dan Kanada, Merck KGaA tetap memegang hak untuk memakai nama Merck di luar Amerika Serikat dan Kanada. Merck & Co. merupakan perusahaan farmasi dengan kapitalisasi pasar dan pendapatan terbesar ketujuh di dunia. Kantor pusatnya terletak di Kenilworth, New Jersey. Perusahaan ini menempati peringkat ke-78 dalam daftar Fortune 500 tahun 2018.
Merck & Co. menerbitkan The Merck Manuals, serangkaian buku referensi medis untuk dokter, perawat, teknisi, dan dokter hewan. The Merck Manuals meliputi Merck Manual of Diagnosis and Therapy, buku referensi medis paling laku di dunia. Merck & Co. sebelumnya juga menerbitkan The Merck Index, sebuah kompendium senyawa kimia, yang kemudian diakuisisi oleh Royal Society of Chemistry pada tahun 2012.
Sejarah
Awal mula
Merck & Co. memulai sejarahnya dari Merck KGaA, yang didirikan oleh keluarga Merck pada tahun 1668 saat Friedrich Jacob Merck membeli sebuah apotek di Darmstadt. Pada abad ke-19, Merck berevolusi dari sebuah apotek menjadi sebuah perusahaan farmasi besar dan memperkenalkan produksi morfin secara komersial.
Pada tahun 1891, George (Georg) Merck beremigrasi ke Amerika Serikat dan mendirikan Merck & Co. di New York. Perusahaan tersebut pun beroperasi dari tahun 1891 hingga 1917 sebagai anak usaha dari Merck KGaA.
Nasionalisasi
Setelah Amerika Serikat masuk ke Perang Dunia I, Merck & Co. disita berdasarkan Undang-Undang Berdagang dengan Lawan tahun 1917. George W. Merck lalu membeli kembali perusahaan tersebut pada tahun 1919, tetapi Merck & Co. tidak lagi menjadi anak usaha dari Merck KGaA. Merck & Co. memegang hak atas nama dagang "Merck" di Amerika Serikat dan Kanada, sementara Merck KGaA memegang hak atas nama dagang tersebut di luar Amerika Serikat dan Kanada.
Pada tahun 1929, H. K. Mulford Company bergabung dengan Sharp and Dohme, Inc. dan membawa teknologi vaksin, termasuk imunisasi untuk kuda kavaleri pada Perang Dunia I dan pengantaran antitoksin difteri ke Merck & Co. H.K. Mulford Company adalah sebuah produsen vaksin cacar dan pada tahun 1902, vaksin cacar Mulford ditemukan berasal dari cacar kuda.
1950 - 2000
Pada tahun 1953, Merck & Co. bergabung dengan Sharp & Dohme, Inc., sehingga menjadi produsen obat terbesar di Amerika Serikat. Perusahaan hasil penggabungan tetap memakai nama dagang Merck di Amerika Serikat dan Kanada, tetapi memakai nama dagang Merck Sharp & Dohme (MSD) di luar Amerika Utara.
Pada tahun 1965, Merck & Co. mengakuisisi Charles E. Frosst Ltd. asal Montreal, Quebec, Kanada (didirikan pada tahun 1899) untuk membentuk Merck-Frosst Canada, Inc., sebagai anak usaha dan pusat risetnya di Kanada. Merck & Co. menutup pusat risetnya di Kanada pada bulan Juli 2010, dan perusahaan tersebut pun diubah namanya menjadi Merck Canada pada tahun 2011.
Merck & Co. didaftarkan sebagai sebuah badan hukum di New Jersey pada tahun 1970. Merck & Co. memiliki sebuah anak usaha, yakni KBI Inc., yang awalnya didirikan sebagai sebuah perusahaan patungan dengan AstraZeneca. Selama akhir dekade 1980-an dan 1990-an, perusahaan ini juga mendirikan perusahaan patungan dengan DuPont untuk dapat mengakses keahlian riset dan pengembangan, serta dengan Johnson & Johnson untuk menjual obat bebas. Pada bulan November 1993, Merck & Co. menyelesaikan pembelian seharga $6 miliar terhadap Medco Containment Services Inc. Merck & Co. memisahkan Medco sepuluh tahun kemudian.
2001 - 2014
Pada bulan November 2009, Merck & Co. mengumumkan bahwa mereka akan bergabung dengan Schering-Plough dalam sebuah kesepakatan senilai US$41 miliar. Walaupun pada kenyataannya, Merck & Co. mengakuisisi Schering-Plough, akuisisi tersebut dilaporkan sebagai sebuah "merger terbalik", di mana Merck & Co. diubah namanya menjadi Merck Sharp & Dohme, sementara Schering-Plough diubah namanya menjadi "Merck & Co., Inc. Manuver tersebut merupakan sebuah upaya untuk mempertahankan hak Schering-Plough untuk memasarkan Remicade, yang pada akhirnya diputuskan melalui arbitrase. Penggabungan tersebut akhirnya selesai pada tanggal 4 November 2009. Hingga 2015, Merck Sharp & Dohme tetap menjadi anak usaha Merck & Co.
Hingga bulan Desember 2013, Merck & Co. mempekerjakan sekitar 76.000 orang di 120 negara dengan 31 pabrik di seluruh dunia. Perusahaan ini merupakan salah satu perusahaan farmasi terbesar di dunia. The Merck Company Foundation telah mendistribusikan lebih dari $480 juta ke sejumlah organisasi pendidikan dan organisasi nirlaba sejak pertama kali didirikan pada tahun 1957 (dan $740 juta secara keseluruhan). Pada tanggal 7 Desember 2012, The Merck Company Foundation mengumumkan bahwa mereka mengakhiri donasinya ke Boy Scouts of America, karena organisasi tersebut "memiliki kebijakan untuk mengeluarkan anggotanya atas alasan orientasi seksual", yang "secara langsung tidak sesuai dengan panduan pemberian donasi dari Merck Foundation". Pada bulan Oktober 2013, Merck & Co. mengumumkan bahwa mereka akan mengurangi 8.500 pegawai sebagai upaya untuk mengurangi biaya operasional sebesar $2,5 miliar (£1,5 miliar) pada tahun 2015. Harga saham perusahaan ini pun naik 2,35% menjadi US$48,73 setelah pengurangan pegawai tersebut diumumkan. Pengurangan tersebut, jika dìgabungkan dengan pengurangan 7.500 pegawai yang diumumkan pada tahun 2011 dan 2012, menjadikan total pengurangannya mencapai 20% dari total pegawainya.
Pada bulan Juni 2014, Merck & Co. mengumumkan bahwa mereka mengakuisisi Idenix Pharmaceuticals dengan harga sekitar $3,85 miliar. Pada bulan Desember 2014, Merck & Co. mengumumkan bahwa mereka akan mengeluarkan dana sebesar $8,4 miliar untuk membeli Cubist Pharmaceuticals.
Catatan dan referensi
Pranala luar
About Merck & Co.
The Merck Manuals
Data bisnis Merck & Co.:
Merck in Canada
Sumber: Wikipedia, CC BY-SA 4.0 · Lihat di Wikipedia ↗
MRK Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
MRK Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
Dividen Yield, rasio pembayaran, riwayat dividen, CAGR 5 tahun
| Tanggal ex-dividen | Jumlah |
|---|---|
| 15 Juni 2026 | $0,8500 |
| 16 Maret 2026 | $0,8500 |
| 15 Des. 2025 | $0,8500 |
| 15 Sep. 2025 | $0,8100 |
| 16 Juni 2025 | $0,8100 |
| 17 Maret 2025 | $0,8100 |
| 16 Des. 2024 | $0,8100 |
| 16 Sep. 2024 | $0,7700 |
| 17 Juni 2024 | $0,7700 |
| 14 Maret 2024 | $0,7700 |
| 14 Des. 2023 | $0,7700 |
| 14 Sep. 2023 | $0,7300 |
| 14 Juni 2023 | $0,7300 |
| 14 Maret 2023 | $0,7300 |
| 14 Des. 2022 | $0,7300 |
| 14 Sep. 2022 | $0,6900 |
| 14 Juni 2022 | $0,6900 |
| 14 Maret 2022 | $0,6900 |
| 14 Des. 2021 | $0,6900 |
| 14 Sep. 2021 | $0,6500 |
MRK Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
- Beli Kuat 9 25,0%
- Beli 16 44,4%
- Tahan 11 30,6%
- Jual 0 0,0%
- Jual Kuat 0 0,0%
Target Harga 12 Bulan
26 analis · 2026-08-22Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
| Periode | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|
| 30 Juni 2026 | $-0.13 | $-0.27 | 0.14% |
| 31 Maret 2026 | $-1.28 | $-1.52 | 0.24% |
| 31 Des. 2025 | $2.09 | $2.03 | 0.06% |
| 30 Sep. 2025 | $2.68 | $2.37 | 0.31% |
| 30 Juni 2025 | $2.19 | $2.03 | 0.16% |
| 31 Maret 2025 | $2.22 | $2.16 | 0.06% |
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| MRK | — | 14.5 | 1.3% | 28.1% | 36.9% | — |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
| JNJ | — | 18.8 | 6.0% | 28.5% | 35.0% | 67.9% |
| PFE | — | 18.3 | -1.7% | 12.4% | 8.9% | — |
| BMY | — | 15.6 | -0.22% | 14.6% | 40.5% | — |
| RPRX | — | 21.7 | 5.1% | 32.4% | 8.0% | — |
| ZTS | $53.46B | 20.9 | 2.3% | 28.2% | 66.0% | — |
| VTRS | — | -4.2 | -3.0% | -24.6% | -23.2% | 35.1% |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | — |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi 15
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.01B | $64.17B | $60.12B | $59.28B | $48.70B | $41.52B | $39.12B | $42.29B | $40.12B | $39.81B | $39.50B | $42.24B | |
| Cost of Revenue | $16.38B | $15.19B | $16.13B | $17.41B | $13.63B | $13.62B | $12.02B | $13.51B | $12.91B | $14.03B | $14.93B | $16.77B | |
| R&D Expense | $15.79B | $17.94B | $30.53B | $13.55B | $12.24B | $13.40B | $9.72B | $9.75B | $10.34B | $10.26B | $6.70B | $7.18B | |
| SG&A Expense | $10.73B | $10.82B | $10.50B | $10.04B | $9.63B | $8.96B | $9.46B | $10.10B | $10.07B | $10.02B | $10.31B | $11.61B | |
| Interest Expense | · | · | $1.15B | $962M | $806M | $831M | $893M | $772M | $754M | $693M | $672M | $732M | |
| Interest Income | $343M | $415M | $365M | $157M | $36M | $59M | $274M | $343M | $385M | $328M | $289M | $266M | |
| Other Non-op | $-151M | $24M | $-466M | $-1.50B | $1.34B | $890M | $-129M | $402M | $500M | $-189M | $-1.53B | $11.61B | |
| Pretax Income | $21.07B | $19.94B | $1.89B | $16.44B | $13.88B | $5.86B | $7.17B | $8.70B | $6.52B | $4.66B | $5.40B | $17.28B | |
| Income Tax | $2.80B | $2.80B | $1.51B | $1.92B | $1.52B | $1.34B | $1.56B | $2.51B | $4.10B | $718M | $942M | $5.35B | |
| Net Income | $18.25B | $17.12B | $365M | $14.52B | $13.05B | $7.07B | $9.84B | $6.22B | $2.39B | $3.92B | $4.44B | $11.92B | |
| EPS (Basic) | $7.30 | $6.76 | $0.14 | $5.73 | $5.16 | $2.79 | $3.84 | $2.34 | $0.88 | $1.42 | $1.58 | $4.12 | |
| EPS (Diluted) | $7.28 | $6.74 | $0.14 | $5.71 | $5.14 | $2.78 | $3.81 | $2.32 | $0.87 | $1.41 | $1.56 | $4.07 | |
| Shares (Basic) | 2,502,000,000 | 2,532,000,000 | 2,537,000,000 | 2,532,000,000 | 2,530,000,000 | 2,530,000,000 | 2,565,000,000 | 2,664,000,000 | 2,730,000,000 | 2,766,000,000 | 2,816,000,000 | 2,894,000,000 | |
| Shares (Diluted) | 2,507,000,000 | 2,541,000,000 | 2,547,000,000 | 2,542,000,000 | 2,538,000,000 | 2,541,000,000 | 2,580,000,000 | 2,679,000,000 | 2,748,000,000 | 2,787,000,000 | 2,841,000,000 | 2,928,000,000 | |
| EBITDA | · | · | · | · | · | · | $3.65B | $4.52B | $4.64B | $5.44B | $6.38B | $6.69B |
Neraca 26
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $14.56B | $13.24B | $6.84B | $12.69B | $8.10B | $8.05B | $9.68B | $7.96B | $6.09B | $6.51B | $8.52B | $7.44B | |
| Short-term Investments | $0 | $447M | $252M | $498M | $0 | $0 | $774M | $899M | $2.41B | $7.83B | $4.90B | $8.28B | |
| Receivables | $11.78B | $10.28B | $10.35B | $9.45B | $9.23B | $6.80B | $6.78B | $7.07B | $6.87B | $7.02B | $6.48B | $6.63B | |
| Inventory | $6.66B | $6.11B | $6.36B | $5.91B | $5.95B | $5.55B | $5.98B | $5.44B | $5.10B | $4.87B | $4.70B | $5.57B | |
| Other Current Assets | $10.52B | $8.71B | $8.37B | $7.17B | $6.99B | $4.67B | $4.28B | $4.50B | $4.30B | $4.39B | $5.14B | $4.69B | |
| Current Assets | $43.52B | $38.78B | $32.17B | $35.72B | $30.27B | $27.76B | $27.48B | $25.88B | $24.77B | $30.61B | $29.75B | $32.60B | |
| PP&E (Net) | $25.32B | $23.78B | $23.05B | $21.42B | $19.28B | $17.00B | $14.30B | $13.29B | $12.44B | $12.03B | $12.51B | $13.14B | |
| PP&E (Gross) | $47.23B | $42.93B | $41.32B | $39.41B | $37.47B | $35.16B | $32.74B | $29.61B | $29.04B | $27.77B | $28.43B | $31.14B | |
| Accum. Depreciation | $21.91B | $19.16B | $18.27B | $17.98B | $18.19B | $18.16B | $17.69B | $16.32B | $16.60B | $15.75B | $15.92B | $18.00B | |
| Goodwill | $21.58B | $21.67B | $21.20B | $21.20B | $21.26B | $18.88B | $18.07B | $18.25B | $18.28B | $18.16B | $17.72B | $12.99B | |
| Intangibles | $26.68B | $16.37B | $18.01B | $20.27B | $22.93B | $14.10B | $14.20B | $13.10B | $14.18B | $17.30B | $22.60B | $20.39B | |
| Other Non-current Assets | $18.82B | $16.04B | $12.00B | $9.53B | · | · | · | · | · | · | · | · | |
| Total Assets | $136.87B | $117.11B | $106.67B | $109.16B | $105.69B | $91.59B | $84.40B | $82.64B | $87.87B | $95.38B | $101.68B | $98.17B | |
| Accounts Payable | $4.40B | $4.08B | $3.92B | $4.26B | $4.61B | $4.33B | $3.74B | $3.32B | $3.10B | $2.81B | $2.53B | $2.62B | |
| Current Liabilities | $28.33B | $28.42B | $25.69B | $24.24B | $23.87B | $27.33B | $22.22B | $22.21B | $18.61B | $17.20B | $19.20B | $18.40B | |
| Capital Leases | $901M | $877M | $928M | $1.01B | $1.23B | $1.33B | $768M | · | · | · | · | · | |
| Deferred Tax | $1.44B | $1.39B | $871M | $1.79B | $3.44B | $1.00B | $1.47B | $1.70B | $2.22B | $5.08B | $6.54B | $4.47B | |
| Other Non-current Liabilities | $7.69B | $6.46B | $8.79B | $8.32B | $9.43B | $12.31B | $11.97B | $12.04B | $11.12B | $8.51B | $7.34B | $7.81B | |
| Long-term Debt | $49.05B | $36.96B | $34.98B | $30.45B | $32.99B | $27.66B | $24.64B | · | $24.35B | $24.57B | $26.13B | $19.70B | |
| Total Debt | $49.05B | $36.96B | · | $30.45B | $32.99B | $27.66B | $24.64B | $19.81B | $24.35B | $24.57B | $26.23B | $19.70B | |
| Common Stock | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | |
| Retained Earnings | $73.08B | $63.07B | $53.90B | $61.08B | $53.70B | $47.36B | $46.60B | $42.58B | $41.35B | $44.13B | $45.35B | $46.02B | |
| Treasury Stock | $63.00B | $58.30B | $57.45B | $56.49B | $57.11B | $56.79B | $55.95B | $50.93B | $43.79B | $40.55B | $38.53B | $35.26B | |
| AOCI | $-4.29B | $-4.95B | $-5.16B | $-4.77B | $-4.43B | $-6.63B | $-6.19B | $-5.54B | $-4.91B | $-5.23B | $-4.15B | $-4.32B | |
| Stockholders' Equity | $52.61B | $46.31B | $37.58B | $45.99B | $38.18B | $25.32B | $25.91B | $26.70B | $34.34B | $40.09B | $44.68B | $48.65B | |
| Liabilities + Equity | $136.87B | $117.11B | $106.67B | $109.16B | $105.69B | $91.59B | $84.40B | $82.64B | $87.87B | $95.38B | $101.68B | $98.17B |
Arus Kas 18
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | $3.65B | $4.52B | $4.68B | $5.47B | $6.38B | $6.69B | |
| Stock-based Comp | $820M | $761M | $645M | $541M | $479M | $441M | $388M | $348M | $312M | $300M | $299M | $278M | |
| Deferred Tax | $-1.67B | $-1.25B | $-1.90B | $-1.57B | $187M | $-566M | $-560M | $-509M | $-2.62B | $-1.52B | $-764M | $-2.60B | |
| Amort. of Intangibles | $2.80B | $2.40B | $2.00B | $2.10B | $1.60B | $1.80B | $1.70B | $3.10B | $3.20B | $3.80B | $4.80B | $4.20B | |
| Restructuring | $889M | $309M | $599M | $337M | $661M | $575M | $626M | $632M | $776M | $651M | $619M | $1.01B | |
| Other Non-cash | · | · | · | · | · | · | $84M | $344M | $1.73B | $2.24B | $2.07B | $-8.43B | |
| Operating Cash Flow | $16.47B | $21.47B | $13.01B | $19.09B | $13.12B | $7.62B | $8.88B | $10.92B | $6.45B | $10.38B | $12.54B | $7.99B | |
| CapEx | $4.11B | $3.37B | $3.86B | $4.39B | $4.45B | $4.43B | $3.37B | $2.62B | $1.89B | $1.61B | $1.28B | $1.32B | |
| Investing Cash Flow | $-13.74B | $-7.73B | $-14.08B | $-4.96B | · | $-9.44B | $-2.63B | $4.31B | $2.68B | $-3.21B | $-4.76B | $-374M | |
| Debt Issued | · | · | $5.94B | $0 | $7.94B | $4.42B | $4.96B | $0 | $0 | $1.08B | $7.94B | $3.15B | |
| Net Debt Issued | $-2.50B | $-1.29B | · | $-2.25B | $5.62B | $2.46B | $4.96B | $-4.29B | $-1.10B | $-1.31B | $5.03B | $-3.47B | |
| Stock Repurchased | $5.08B | $1.31B | $1.35B | $0 | $840M | $1.28B | $4.78B | $9.09B | $4.01B | $3.43B | $4.19B | $7.70B | |
| Net Stock Activity | $-5.08B | $-1.31B | · | $0 | $-840M | $-1.28B | $-4.78B | $-9.09B | $-4.01B | $-3.43B | $-4.19B | $-7.70B | |
| Dividends Paid | $8.18B | $7.84B | $7.45B | $7.01B | $6.61B | $6.21B | $5.70B | $5.17B | $5.17B | $5.12B | $5.12B | $5.17B | |
| Financing Cash Flow | $-1.92B | $-7.03B | $-4.81B | $-9.12B | · | $-2.83B | $-8.86B | $-13.16B | $-10.01B | $-9.04B | $-5.39B | $-15.24B | |
| Net Change in Cash | $1.37B | $6.41B | $-5.86B | $4.61B | $14M | $-1.77B | $1.97B | $1.87B | $-419M | $-2.01B | $1.08B | $-8.18B | |
| Free Cash Flow | $12.36B | $18.10B | · | $14.71B | $8.67B | $5.57B | $9.97B | $8.31B | $4.56B | $8.76B | $11.14B | $6.54B | |
| Levered FCF | · | · | · | $13.86B | $7.96B | $4.90B | $9.21B | $7.76B | $4.28B | $8.18B | $10.58B | $6.04B |
Profitabilitas 5
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 28.1% | 26.7% | · | 24.5% | 26.8% | 14.7% | 21.0% | 14.7% | 6.0% | 9.8% | 11.2% | 28.2% | |
| Pretax Margin | 32.4% | 31.1% | · | 27.7% | 28.5% | 18.3% | 24.5% | 20.6% | 16.2% | 11.7% | 13.7% | 40.9% | |
| EBITDA Margin | · | · | · | · | · | · | 7.8% | 10.7% | 11.6% | 13.7% | 16.1% | 15.8% | |
| ROA | 14.4% | 15.3% | · | 13.5% | 13.2% | 8.0% | 11.8% | 7.3% | 2.6% | 4.0% | 4.4% | 11.7% | |
| ROE | 36.9% | 40.8% | · | 34.5% | 41.1% | 27.6% | 37.4% | 20.4% | 6.4% | 9.2% | 9.5% | 24.2% |
Likuiditas & Solvabilitas 4
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.5 | 1.4 | · | 1.5 | 1.3 | 1.0 | 1.2 | 1.2 | 1.3 | 1.8 | 1.6 | 1.8 | |
| Quick Ratio | 0.9 | 0.8 | · | 0.9 | 0.7 | 0.6 | 0.8 | 0.7 | 0.8 | 1.2 | 1.0 | 1.2 | |
| Debt / Equity | 0.9 | 0.8 | · | 0.7 | 0.9 | 1.1 | 1.0 | 0.7 | 0.7 | 0.6 | 0.6 | 0.4 | |
| LT Debt / Equity | 0.9 | 0.7 | · | 0.6 | 0.8 | 1.0 | 0.9 | 0.7 | 0.6 | 0.6 | 0.5 | 0.4 |
Efisiensi 3
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.6 | · | 0.6 | 0.5 | 0.5 | 0.6 | 0.5 | 0.4 | 0.4 | 0.4 | 0.4 | |
| Inventory Turnover | 2.6 | 2.4 | · | 2.9 | 2.4 | 2.5 | 2.5 | 2.6 | 2.6 | 2.9 | 2.9 | 2.8 | |
| Receivables Turnover | 5.9 | 6.2 | · | 6.3 | 6.1 | 6.6 | 6.8 | 6.1 | 5.8 | 5.9 | 6.0 | 6.1 |
Tingkat Pertumbuhan 10
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 1.3% | 6.7% | 1.4% | 21.7% | 17.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 3.1% | 9.6% | 13.1% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 9.4% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 8.0% | 4714.3% | -97.5% | 11.1% | 84.9% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 8.4% | 9.4% | -63.1% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 21.2% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 6.6% | 4589.6% | -97.5% | 11.3% | 84.7% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 7.9% | 9.5% | -62.8% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 20.9% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 5.6% | · | · | · | · | · | · | · | · | · | · | · |
Valuasi (TTM) 6
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $65.01B | $64.17B | $60.12B | $59.28B | $48.70B | $41.52B | $39.12B | $42.29B | $40.12B | $39.81B | $39.50B | $42.24B | |
| Net Income TTM | $18.25B | $17.12B | $365M | $14.52B | $13.05B | $7.07B | $9.84B | $6.22B | $2.39B | $3.92B | $4.44B | $11.92B | |
| P/E | 14.5 | 14.8 | 778.7 | 19.4 | 14.9 | 28.1 | 22.8 | 31.4 | 61.7 | 39.8 | 32.3 | 13.3 | |
| Earnings Yield | 6.9% | 6.8% | 0.13% | 5.1% | 6.7% | 3.6% | 4.4% | 3.2% | 1.6% | 2.5% | 3.1% | 7.5% | |
| Payout Ratio | 44.8% | 45.8% | · | 48.3% | 50.7% | 87.9% | 57.9% | 83.2% | 215.8% | 130.7% | 115.2% | 43.4% | |
| Annual Payout | $8.18B | $7.84B | $7.45B | $7.01B | $6.61B | $6.21B | $5.70B | $5.17B | $5.17B | $5.12B | $5.12B | $5.17B |
Laporan Laba Rugi 14
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.61B | $16.29B | $16.40B | $17.28B | $15.81B | $15.53B | $15.62B | $16.66B | $16.11B | $15.78B | $14.63B | $15.96B | $15.04B | $14.49B | $13.83B | $14.96B | |
| Cost of Revenue | $4.39B | $4.20B | $5.55B | $3.85B | $3.56B | $3.42B | $3.83B | $4.08B | $3.75B | $3.54B | $3.91B | $4.26B | $4.02B | $3.93B | $3.88B | $3.93B | |
| R&D Expense | $9.74B | $12.59B | $3.89B | $4.23B | $4.05B | $3.62B | $4.58B | $5.86B | $3.50B | $3.99B | $9.63B | $3.31B | $13.32B | $4.28B | $3.77B | $4.40B | |
| SG&A Expense | $2.90B | $2.70B | $2.90B | $2.63B | $2.65B | $2.55B | $2.86B | $2.73B | $2.74B | $2.48B | $2.80B | $2.52B | $2.70B | $2.48B | $2.69B | $2.52B | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $303M | · | $317M | $277M | $242M | · | $244M | |
| Interest Income | $35M | $35M | $69M | $96M | $69M | $109M | $146M | $127M | $69M | $73M | $71M | $73M | $109M | $112M | $95M | $40M | |
| Other Non-op | $-99M | $-138M | $-431M | $238M | $7M | $35M | $-129M | $162M | $-42M | $33M | $-79M | $-126M | $-172M | $-89M | $74M | $-429M | |
| Pretax Income | $-683M | $-3.53B | $3.42B | $6.75B | $5.00B | $5.90B | $4.17B | $4.09B | $6.01B | $5.67B | $-2.05B | $5.62B | $-5.33B | $3.65B | $3.51B | $3.58B | |
| Income Tax | $654M | $709M | $457M | $958M | $571M | $818M | $426M | $929M | $545M | $903M | $-820M | $870M | $637M | $825M | $496M | $330M | |
| Net Income | $-1.33B | $-4.24B | $2.96B | $5.79B | $4.43B | $5.08B | $3.74B | $3.16B | $5.46B | $4.76B | $-1.23B | $4.75B | $-5.97B | $2.82B | $3.02B | $3.25B | |
| EPS (Basic) | $-0.54 | $-1.72 | $1.21 | $2.32 | $1.76 | $2.01 | $1.48 | $1.25 | $2.15 | $1.88 | $-0.49 | $1.87 | $-2.35 | $1.11 | $1.19 | $1.28 | |
| EPS (Diluted) | $-0.54 | $-1.72 | $1.19 | $2.32 | $1.76 | $2.01 | $1.49 | $1.24 | $2.14 | $1.87 | $-0.48 | $1.86 | $-2.35 | $1.11 | $1.18 | $1.28 | |
| Shares (Basic) | 2,470,000,000 | 2,472,000,000 | -5,026,000,000 | 2,495,000,000 | 2,510,000,000 | 2,523,000,000 | -5,069,000,000 | 2,534,000,000 | 2,534,000,000 | 2,533,000,000 | -5,077,000,000 | 2,537,000,000 | 2,539,000,000 | 2,538,000,000 | -5,060,000,000 | 2,533,000,000 | |
| Shares (Diluted) | 2,470,000,000 | 2,472,000,000 | -5,035,000,000 | 2,498,000,000 | 2,513,000,000 | 2,531,000,000 | -5,088,000,000 | 2,541,000,000 | 2,544,000,000 | 2,544,000,000 | -5,089,000,000 | 2,546,000,000 | 2,539,000,000 | 2,551,000,000 | -5,077,000,000 | 2,542,000,000 |
Neraca 26
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.85B | $5.33B | $14.56B | $18.17B | $8.01B | $8.63B | $13.24B | $14.59B | $11.30B | $5.58B | · | $8.61B | $5.66B | $9.71B | · | $11.14B | |
| Short-term Investments | $292M | $375M | $0 | $45M | $615M | $599M | $447M | $0 | $50M | $40M | · | $168M | $718M | $680M | · | $103M | |
| Receivables | $12.56B | $12.21B | $11.78B | $12.12B | $11.85B | $10.79B | $10.28B | $11.38B | $11.64B | $11.37B | · | $10.39B | $11.03B | $10.41B | · | $9.48B | |
| Inventory | $6.21B | $6.48B | $6.66B | $6.44B | $6.60B | $6.20B | $6.11B | $6.24B | $6.47B | $6.51B | · | $6.13B | $5.93B | $5.86B | · | $5.61B | |
| Other Current Assets | $10.77B | $10.62B | $10.52B | $10.78B | $10.00B | $9.29B | $8.71B | $8.14B | $8.74B | $7.95B | · | $6.66B | · | · | · | · | |
| Current Assets | $36.68B | $35.02B | $43.52B | $47.56B | $37.06B | $35.50B | $38.78B | $40.36B | $38.20B | $31.45B | · | $31.95B | $29.98B | $33.40B | · | $33.56B | |
| PP&E (Net) | $25.74B | $25.43B | $25.32B | $25.64B | $25.24B | $24.79B | $23.78B | $23.45B | $23.22B | $23.05B | $23.05B | $22.53B | $22.23B | $21.76B | $21.42B | $20.42B | |
| PP&E (Gross) | · | · | $47.23B | · | · | · | $42.93B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $22.73B | $22.29B | $21.91B | $20.61B | $20.26B | $19.68B | $19.16B | $19.07B | $18.96B | $18.62B | · | $18.45B | $18.43B | $18.26B | · | $17.92B | |
| Goodwill | $21.58B | $21.58B | $21.58B | $21.59B | $21.59B | $21.68B | $21.67B | $21.70B | $21.16B | $21.18B | $21.20B | $21.18B | $21.20B | $21.21B | $21.20B | $21.16B | |
| Intangibles | $24.98B | $25.75B | $26.68B | $15.31B | $15.19B | $15.76B | $16.37B | $17.01B | $16.98B | $17.57B | · | $19.20B | $19.66B | $19.86B | · | $21.37B | |
| Other Non-current Assets | $19.60B | $19.81B | $18.82B | $18.33B | $17.66B | $16.77B | $16.04B | $14.44B | $12.70B | $12.33B | · | $10.56B | · | · | · | · | |
| Total Assets | $129.80B | $128.69B | $136.87B | $129.55B | $117.52B | $115.12B | $117.11B | $117.53B | $112.63B | $105.85B | · | $106.73B | $104.47B | $107.80B | · | $107.08B | |
| Accounts Payable | $3.83B | $3.86B | $4.40B | $4.15B | $3.89B | $3.78B | $4.08B | $3.59B | $3.52B | $3.51B | · | $3.51B | $3.44B | $3.68B | · | $3.37B | |
| Current Liabilities | $27.73B | $26.95B | $28.33B | $28.63B | $26.04B | $25.17B | $28.42B | $29.59B | $26.06B | $25.10B | · | $23.09B | $23.39B | $23.13B | · | $23.00B | |
| Capital Leases | · | · | $901M | · | · | · | $877M | · | · | · | · | · | · | · | · | · | |
| Deferred Tax | $1.43B | $1.49B | $1.44B | $1.38B | $1.43B | $1.41B | $1.39B | $864M | $876M | $922M | · | $1.02B | $996M | $1.44B | · | $2.42B | |
| Other Non-current Liabilities | $7.57B | $7.64B | $7.69B | $7.66B | $7.03B | $6.66B | $6.46B | $7.54B | $7.33B | $8.26B | · | $7.34B | $7.26B | $8.24B | · | $8.66B | |
| Long-term Debt | · | · | $49.05B | · | · | · | $36.96B | · | · | · | · | · | · | · | · | · | |
| Total Debt | $51.08B | $46.67B | · | $39.97B | $33.97B | $33.48B | · | $34.98B | $34.72B | $31.14B | · | $33.97B | $34.07B | $28.07B | · | $28.48B | |
| Common Stock | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | · | $1.79B | $1.79B | $1.79B | · | $1.79B | |
| Retained Earnings | $63.27B | $66.72B | $73.08B | $72.23B | $68.48B | $66.10B | $63.07B | $61.38B | $60.19B | $56.70B | · | $57.08B | $54.20B | $62.04B | · | $59.93B | |
| Treasury Stock | $64.13B | $63.75B | $63.00B | $61.80B | $60.49B | $59.40B | $58.30B | $57.83B | $57.39B | $57.45B | · | $57.07B | $56.61B | $56.58B | · | $56.76B | |
| AOCI | $-3.94B | $-4.06B | $-4.29B | $-5.20B | $-5.42B | $-4.96B | $-4.95B | $-5.37B | $-5.36B | $-5.27B | · | $-4.92B | $-4.90B | $-4.88B | · | $-4.74B | |
| Stockholders' Equity | $41.93B | $45.88B | $52.61B | $51.85B | $48.99B | $48.34B | $46.31B | $44.50B | $43.58B | $40.36B | · | $41.25B | $38.69B | $46.83B | · | $44.46B | |
| Liabilities + Equity | $129.80B | $128.69B | $136.87B | $129.55B | $117.52B | $115.12B | $117.11B | $117.53B | $112.63B | $105.85B | · | $106.73B | $104.47B | $107.80B | · | $107.08B |
Arus Kas 15
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $298M | $185M | $205M | $204M | $216M | $195M | $187M | $195M | $203M | $176M | $167M | $164M | $169M | $145M | $145M | $139M | |
| Deferred Tax | $-544M | $-315M | $-825M | $-212M | $-448M | $-186M | $-616M | $-401M | $-181M | $-51M | $-931M | $-336M | $-355M | $-277M | $-307M | $-661M | |
| Restructuring | $151M | $195M | $213M | $47M | $560M | $69M | $50M | $56M | $80M | $123M | $255M | $126M | $151M | $67M | $48M | $94M | |
| Operating Cash Flow | $5.37B | $3.92B | $2.86B | $7.82B | $3.29B | $2.50B | $3.45B | $9.29B | $5.64B | $3.09B | $246M | $7.72B | $3.70B | $1.34B | $4.43B | $5.60B | |
| CapEx | $893M | $991M | $1.03B | $987M | $764M | $1.33B | $937M | $783M | $791M | $861M | $989M | $902M | $965M | $1.01B | $1.15B | $1.13B | |
| Investing Cash Flow | $-5.60B | $-10.21B | $-11.20B | $-283M | $-770M | $-1.49B | $-1.44B | $-3.85B | $-1.07B | $-1.38B | $53M | $-334M | $-11.44B | $-2.36B | $-1.75B | $-962M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | · | · | $-7M | · | · | · | $0 | |
| Net Debt Issued | · | $-1.14B | · | · | · | $-2.50B | · | · | · | $-751M | · | · | · | $-1M | · | · | |
| Stock Repurchased | $757M | $874M | $1.25B | $1.32B | $1.34B | $1.16B | $489M | $444M | $251M | $122M | $393M | $466M | $338M | $149M | $0 | $0 | |
| Net Stock Activity | · | $-874M | · | · | · | $-1.16B | · | · | · | $-122M | · | · | · | $-149M | · | · | |
| Dividends Paid | $2.14B | $2.10B | $2.02B | $2.03B | $2.08B | $2.05B | $1.95B | $1.95B | $1.99B | $1.95B | $1.85B | $1.85B | $1.89B | $1.85B | $1.75B | $1.75B | |
| Financing Cash Flow | $1.76B | $-2.98B | $4.75B | $2.64B | $-3.56B | $-5.75B | $-3.01B | $-2.42B | $1.22B | $-2.81B | $-2.25B | $-4.27B | $3.76B | $-2.05B | $-1.55B | $-2.70B | |
| Net Change in Cash | $1.49B | $-9.29B | $-3.57B | $10.19B | $-659M | $-4.59B | $-1.37B | $3.31B | $5.70B | $-1.24B | $-1.76B | $2.96B | $-4.07B | $-2.99B | $1.49B | $1.53B | |
| Free Cash Flow | · | $2.93B | · | · | · | $1.17B | · | · | · | $2.23B | · | · | · | $332M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $1.97B | · | · | · | $145M | · | · |
Profitabilitas 4
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | -8.0% | -26.0% | · | 33.5% | 28.0% | 32.7% | · | 18.9% | 33.9% | 30.2% | · | 29.7% | -39.7% | 19.5% | · | 21.7% | |
| Pretax Margin | -4.1% | -21.7% | · | 39.0% | 31.6% | 38.0% | · | 24.6% | 37.3% | 35.9% | · | 35.2% | -35.5% | 25.2% | · | 23.9% | |
| ROA | -1.1% | -3.5% | · | 4.7% | 3.9% | 4.6% | · | 2.8% | 5.0% | 4.5% | · | 4.4% | -5.7% | 2.6% | · | 3.2% | |
| ROE | -2.9% | -9.0% | · | 12.0% | 9.6% | 11.5% | · | 7.4% | 13.3% | 10.9% | · | 11.1% | -14.6% | 6.4% | · | 8.1% |
Likuiditas & Solvabilitas 4
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.3 | · | 1.7 | 1.4 | 1.4 | · | 1.4 | 1.5 | 1.3 | · | 1.4 | 1.3 | 1.4 | · | 1.5 | |
| Quick Ratio | 0.7 | 0.7 | · | 1.1 | 0.8 | 0.8 | · | 0.9 | 0.9 | 0.7 | · | 0.8 | 0.7 | 0.9 | · | 0.9 | |
| Debt / Equity | 1.2 | 1.0 | · | 0.8 | 0.7 | 0.7 | · | 0.8 | 0.8 | 0.8 | · | 0.8 | 0.9 | 0.6 | · | 0.6 | |
| LT Debt / Equity | 1.2 | 1.0 | · | 0.8 | 0.7 | 0.7 | · | 0.8 | 0.8 | 0.8 | · | 0.8 | 0.9 | 0.6 | · | 0.6 |
Efisiensi 3
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.7 | 0.7 | · | 0.6 | 0.5 | 0.5 | · | 0.7 | 0.6 | 0.6 | · | 0.7 | 0.7 | 0.7 | · | 0.7 | |
| Receivables Turnover | 1.4 | 1.4 | · | 1.5 | 1.3 | 1.4 | · | 1.5 | 1.4 | 1.4 | · | 1.6 | 1.5 | 1.4 | · | 1.7 |
Valuasi (TTM) 5
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $65.97B | $64.90B | · | $65.27B | $64.10B | $64.07B | · | $64.51B | $62.88B | $61.26B | · | $60.44B | $59.07B | $59.94B | · | $58.61B | |
| Net Income TTM | $4.64B | $11.05B | · | $18.45B | $18.12B | $18.45B | · | $18.12B | $8.99B | $6.35B | · | $4.84B | $4.04B | $14.32B | · | $16.07B | |
| P/E | 70.6 | 27.5 | · | 11.5 | 11.1 | 12.4 | · | 16.0 | 35.2 | 53.0 | · | 54.2 | 72.6 | 18.9 | · | 13.6 | |
| Earnings Yield | 1.4% | 3.6% | · | 8.7% | 9.0% | 8.1% | · | 6.3% | 2.8% | 1.9% | · | 1.8% | 1.4% | 5.3% | · | 7.3% | |
| Payout Ratio | · | -49.6% | · | · | · | 40.4% | · | · | · | 40.9% | · | · | · | 65.7% | · | · |
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
Laporan Laba Rugi
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Pendapatan | $65.01B | $64.17B | $60.12B | $59.28B | $48.70B |
| Laba Bersih | $18.25B | $17.12B | $365M | $14.52B | $13.05B |
| EPS Dilusian | $7.28 | $6.74 | $0.14 | $5.71 | $5.14 |
Neraca
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Utang / Ekuitas | 0.9 | 0.8 | — | 0.7 | 0.9 |
| Rasio Lancar | 1.5 | 1.4 | — | 1.5 | 1.3 |
| Rasio Cepat | 0.9 | 0.8 | — | 0.9 | 0.7 |
Arus Kas
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Arus Kas Bebas | $12.36B | $18.10B | — | $14.71B | $8.67B |
Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini
- Is Merck & Co. (MRK) One of the Best Cheap Stocks to Buy for Beginners?
- Merck (MRK) Uji Coba Fase 3 TroFuse-005 untuk Kanker Endometrium Memenuhi Titik Akhir Primer
- Analis Mengangkat Target Harga Merck (MRK) sebesar $1 Setelah Mengalahkan Estimasi Kuartal Pertama
- Merck & Co. Inc. (MRK): Salah Satu Saham Pertumbuhan Tinggi Berisiko Rendah Terbaik untuk Dibeli Saat Ini
- Jim Cramer Mengatakan “Merck Sangat Hebat”
- UBS Naikkan Prediksi Harga Merck (MRK) Sebagai Bagian Preview Sektor
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
Pilih metrik yang penting bagi Anda — klik ➕ di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Pemilik institusional (13F) 4.129 pengaju · $150.3B total · Per tanggal 30 Juni 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 176 (-186 vs Kuartal sebelumnya) | 112 (-4 vs Kuartal sebelumnya) | 1.605 (+176 vs Kuartal sebelumnya) | 1.450 (-119 vs Kuartal sebelumnya) | +73.4M |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $20.730.027.859 | 161.323.174 | 13,79% | Saham |
| STATE STREET CORP | $15.573.753.504 | 120.413.256 | 10,36% | Saham |
| WELLINGTON MANAGEMENT GROUP LLP | $10.321.764.299 | 80.325.014 | 6,87% | Saham |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $8.704.457.517 | 67.738.969 | 5,79% | Saham |
| GEODE CAPITAL MANAGEMENT, LLC | $6.751.244.864 | 52.623.892 | 4,49% | Saham |
| Fisher Asset Management, LLC | $4.949.339.962 | 38.516.263 | 3,29% | Saham |
| NORGES BANK | $4.752.416.244 | 36.983.784 | 3,16% | Saham |
| FMR LLC | $3.132.935.933 | 24.380.824 | 2,08% | Saham |
| Capital International Investors | $1.977.446.105 | 15.386.689 | 1,32% | Saham |
| DIMENSIONAL FUND ADVISORS LP | $1.922.817.650 | 14.963.562 | 1,28% | Saham |
| VANGUARD FIDUCIARY TRUST CO | $1.782.206.207 | 13.869.309 | 1,19% | Saham |
| ALLIANCEBERNSTEIN L.P. | $1.579.641.303 | 13.131.942 | 1,05% | Saham |
| AMERIPRISE FINANCIAL INC | $1.522.828.539 | 11.849.396 | 1,01% | Saham |
| BANK OF AMERICA CORP /DE/ | $1.414.766.661 | 11.009.857 | 0,94% | Saham |
| STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | $1.237.455.000 | 9.630.000 | 0,82% | Saham |
| BlackRock, Inc. | $904.381.201 | 7.037.986 | 0,60% | Saham |
| Swiss National Bank | $896.062.754 | 6.973.251 | 0,60% | Saham |
| Grantham, Mayo, Van Otterloo & Co. LLC | $871.873.732 | 6.785.008 | 0,58% | Saham |
| UBS Group AG | $852.504.338 | 6.634.275 | 0,57% | Saham |
| Aristotle Capital Management, LLC | $845.353.780 | 6.578.570 | 0,56% | Saham |
| Mitsubishi UFJ Asset Management Co., Ltd. | $794.576.951 | 6.184.340 | 0,53% | Saham |
| Sumitomo Mitsui Trust Group, Inc. | $792.730.250 | 6.169.107 | 0,53% | Saham |
| Legal & General Group Plc | $786.751.919 | 6.122.583 | 0,52% | Saham |
| GOLDMAN SACHS GROUP INC | $758.234.348 | 5.900.656 | 0,50% | Saham |
| National Pension Service | $744.243.987 | 5.791.782 | 0,50% | Saham |
| VANGUARD ASSET MANAGEMENT, Ltd | $718.733.268 | 5.593.255 | 0,48% | Saham |
| Vanguard Global Advisers, LLC | $708.361.133 | 5.512.538 | 0,47% | Saham |
| California Public Employees Retirement System | $693.738.604 | 5.398.744 | 0,46% | Saham |
| JANE STREET GROUP, LLC | $656.609.300 | 5.109.800 | 0,44% | Opsi jual |
| AMERICAN CENTURY COMPANIES INC | $625.276.901 | 4.865.967 | 0,42% | Saham |
| BARCLAYS PLC | $581.939.240 | 4.528.710 | 0,39% | Saham |
| JANE STREET GROUP, LLC | $575.718.550 | 4.480.300 | 0,38% | Opsi beli |
| Caisse de depot et placement du Quebec | $571.581.750 | 4.448.107 | 0,38% | Saham |
| CANADA PENSION PLAN INVESTMENT BOARD | $536.693.614 | 4.176.604 | 0,36% | Saham |
| VICTORY CAPITAL MANAGEMENT INC | $532.489.223 | 4.143.885 | 0,35% | Saham |
| PeakShares LLC | $516.313.000 | 4.018 | 0,34% | Saham |
| ENVESTNET ASSET MANAGEMENT INC | $513.599.135 | 3.996.890 | 0,34% | Saham |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $509.698.206 | 3.966.523 | 0,34% | Saham |
| LPL Financial LLC | $493.020.235 | 3.836.733 | 0,33% | Saham |
| PNC Financial Services Group, Inc. | $491.367.167 | 3.823.869 | 0,33% | Saham |
| RHUMBLINE ADVISERS | $489.523.018 | 3.809.518 | 0,33% | Saham |
| RAYMOND JAMES FINANCIAL INC | $488.705.089 | 3.803.152 | 0,33% | Saham |
| THORNBURG INVESTMENT MANAGEMENT INC | $486.754.916 | 3.787.976 | 0,32% | Saham |
| Bank Julius Baer & Co. Ltd, Zurich | $480.279.543 | 3.729.950 | 0,32% | Saham |
| HighTower Advisors, LLC | $472.869.672 | 3.679.920 | 0,31% | Saham |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $461.385.767 | 3.835.612 | 0,31% | Saham |
| CITADEL ADVISORS LLC | $447.912.450 | 3.485.700 | 0,30% | Opsi beli |
| NEUBERGER BERMAN GROUP LLC | $443.015.598 | 3.446.800 | 0,29% | Saham |
| Ensign Peak Advisors, Inc | $432.380.784 | 3.364.831 | 0,29% | Saham |
| AVIVA PLC | $419.437.621 | 3.264.106 | 0,28% | Saham |
| NORDEA INVESTMENT MANAGEMENT AB | $407.966.347 | 3.211.322 | 0,27% | Saham |
| BNP PARIBAS FINANCIAL MARKETS | $402.325.404 | 3.130.937 | 0,27% | Saham |
| ROYAL LONDON ASSET MANAGEMENT LTD | $383.834.263 | 2.987.037 | 0,26% | Saham |
| NEW YORK STATE COMMON RETIREMENT FUND | $373.911.742 | 2.909.819 | 0,25% | Saham |
| JENNISON ASSOCIATES LLC | $350.671.044 | 2.728.958 | 0,23% | Saham |
| Assenagon Asset Management S.A. | $347.334.472 | 2.702.992 | 0,23% | Saham |
| Mariner, LLC | $346.849.966 | 2.699.099 | 0,23% | Saham |
| FIRST TRUST ADVISORS LP | $333.053.353 | 2.591.856 | 0,22% | Saham |
| Alyeska Investment Group, L.P. | $318.755.815 | 2.480.590 | 0,21% | Saham |
| JONES FINANCIAL COMPANIES LLLP | $316.128.005 | 2.457.081 | 0,21% | Saham |
| Eurizon Capital SGR S.p.A. | $308.695.812 | 2.398.834 | 0,21% | Saham |
| Robeco Institutional Asset Management B.V. | $305.058.122 | 2.373.993 | 0,20% | Saham |
| MACKENZIE FINANCIAL CORP | $304.985.884 | 2.373.431 | 0,20% | Saham |
| TD Asset Management Inc | $300.012.291 | 2.334.726 | 0,20% | Saham |
| Smead Capital Management, Inc. | $299.979.141 | 2.334.468 | 0,20% | Saham |
| BANK OF MONTREAL /CAN/ | $297.073.239 | 2.311.854 | 0,20% | Saham |
| JANUS HENDERSON GROUP PLC | $284.641.385 | 2.366.293 | 0,19% | Saham |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $275.099.611 | 2.140.853 | 0,18% | Saham |
| BANK OF NOVA SCOTIA | $272.246.099 | 2.118.646 | 0,18% | Saham |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $266.403.116 | 2.073.176 | 0,18% | Saham |
| Aberdeen Group plc | $264.474.588 | 2.058.168 | 0,18% | Saham |
| CAPTRUST FINANCIAL ADVISORS | $263.988.216 | 2.054.383 | 0,18% | Saham |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $260.857.956 | 2.030.023 | 0,17% | Saham |
| Cullen Capital Management, LLC | $259.158.168 | 2.016.795 | 0,17% | Saham |
| APG Asset Management N.V. | $253.945.357 | 2.259.422 | 0,17% | Saham |
| Capital Research Global Investors | $247.364.171 | 1.925.013 | 0,16% | Saham |
| PRUDENTIAL FINANCIAL INC | $245.433.073 | 1.909.985 | 0,16% | Saham |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $244.871.555 | 1.912.337 | 0,16% | Saham |
| Nuveen, LLC | $244.496.631 | 1.902.698 | 0,16% | Saham |
| CITADEL ADVISORS LLC | $243.534.357 | 1.895.209 | 0,16% | Saham |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $242.026.848 | 2.012.028 | 0,16% | Saham |
| Capital Wealth Planning, LLC | $241.414.107 | 1.878.709 | 0,16% | Saham |
| Korea Investment CORP | $239.190.543 | 1.861.405 | 0,16% | Saham |
| LAZARD ASSET MANAGEMENT LLC | $236.603.326 | 1.841.271 | 0,16% | Saham |
| CITIGROUP INC | $218.861.200 | 1.703.200 | 0,15% | Opsi jual |
| STOREBRAND ASSET MANAGEMENT AS | $216.639.564 | 1.685.911 | 0,14% | Saham |
| SEB Asset Management AB | $212.802.920 | 1.656.056 | 0,14% | Saham |
| Alecta Tjanstepension Omsesidigt | $210.598.117 | 1.640.300 | 0,14% | Saham |
| Quantinno Capital Management LP | $195.732.858 | 1.523.212 | 0,13% | Saham |
| FIFTH THIRD BANCORP | $192.829.582 | 1.500.619 | 0,13% | Saham |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $190.474.908 | 1.482.295 | 0,13% | Saham |
| Mondrian Investment Partners LTD | $189.401.933 | 1.473.945 | 0,13% | Saham |
| DJE Kapital AG | $187.479.427 | 1.431.324 | 0,12% | Saham |
| Pictet Asset Management Holding SA | $186.518.393 | 1.451.505 | 0,12% | Saham |
| CIBC WORLD MARKET INC. | $186.004.690 | 1.447.507 | 0,12% | Saham |
| Mitsubishi UFJ Trust & Banking Corp | $184.639.851 | 1.436.886 | 0,12% | Saham |
| TORONTO DOMINION BANK | $184.538.465 | 1.436.097 | 0,12% | Saham |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $183.546.956 | 1.625.531 | 0,12% | Saham |
| Candriam S.C.A. | $182.227.428 | 1.419.478 | 0,12% | Saham |
| Focus Partners Wealth | $176.831.683 | 1.375.512 | 0,12% | Saham |
Orang dalam perusahaan 110 orang dalam · 56 pejabat · 40 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Robert M Davis | Chairman, CEO & President | 5 Mei 2026 A | 450.351 | 0 | 2 | $-5.599.291 |
| Fred Hassan | Chairman and CEO | 3 Nov. 2009 D | 0 | 0 | 0 | $0 |
| Caroline Litchfield | EVP & CFO | 5 Mei 2026 A | 92.301 | 0 | 1 | $-5.023.261 |
| KELLOGG PETER N | Exe V-P & CFO | 24 Feb. 2014 A | 149.554 | 0 | 0 | $0 |
| Joseph Romanelli | President, Human Health Int?l | 26 Jan. 2026 A | 28.739 | 0 | 0 | $0 |
| Brian Foard | EVP, Specialty, Pharma, & ID | 5 Mei 2026 A | — | 0 | 0 | $0 |
| Dalton E. Smart III | SVP Fin. - Global Controller | 5 Mei 2026 A | 9.388 | 0 | 2 | $-765.952 |
| Johannes Jacobus Oosthuizen | EVP, Oncology & Int?l | 5 Mei 2026 A | 21.895 | 0 | 1 | $-1.828.050 |
| Dean Y Li | Executive VP & President, MRL | 5 Mei 2026 A | 94.431 | 0 | 2 | $-2.994.700 |
| Betty D Larson | EVP, Chief HR Officer | 5 Mei 2026 A | 13.774 | 0 | 0 | $0 |
| Sanat Chattopadhyay | Exe V-P & Pres. MMD | 29 April 2026 M | 15.347 | 0 | 0 | $0 |
| Cristal N Downing | Chief Comm. & Public Afrs Ofcr | 10 Nov. 2025 S | 0 | 0 | 1 | $-616.395 |
| Michael A Klobuchar | EVP - Chief Strategy Officer | 4 Mei 2024 M | 23.621 | 0 | 0 | $0 |
| Steven Mizell | EVP, Chief HR Officer | 2 Feb. 2024 M | 23.619 | 0 | 0 | $0 |
| Lisa Lecointe-Cephas | SVP Chief Ethics & Com Officer | 4 Mei 2023 M | 5.142 | 0 | 0 | $0 |
| Rita A Karachun | Sr. VP Fince-Global Controller | 4 Mei 2023 M | 45.710 | 0 | 0 | $0 |
| Kenneth C Frazier | Executive Chair | 7 Nov. 2022 M | 700.653 | 0 | 0 | $0 |
| Arpa Garay | SVP Human Health Global Mktg. | 3 Mei 2022 A | 2.109 | 0 | 0 | $0 |
| Julie L. Gerberding | EVP, Chief Patient Officer | 24 Feb. 2022 A | 48.712 | 0 | 0 | $0 |
| Frank Clyburn | EVP & Pres ? Human Health | 4 Mei 2021 A | 97.095 | 0 | 0 | $0 |
| Michael Fleming | SVP Chief Ethics & Com Officer | 26 Feb. 2021 A | 10.283 | 0 | 0 | $0 |
| Michael Nally | EVP, Chief Marketing Officer | 26 Feb. 2021 A | 19.630 | 0 | 0 | $0 |
| Roger M Perlmutter | Exe V-P & Pres, MRL | 1 Mei 2020 A | 214.428 | 0 | 0 | $0 |
| Clark Golestani | EVP & Chief Info Officer | 10 Agu 2016 S | 14.083 | 0 | 0 | $0 |
| Michael Rosenblatt | Exec V-P & Chief Med Officer | 10 Mei 2016 A | 41.133 | 0 | 0 | $0 |
| Willie A Deese | Exe V-P & Pres. MMD | 22 Feb. 2016 A | 133.759 | 0 | 0 | $0 |
| Bruce N Kuhlik | Exe V-P & Gen Counsel | 4 Mei 2015 M | 150.432 | 0 | 0 | $0 |
| Bridgette P Heller | Exe.VP & Pres.Con.Hlth.Care | 9 Mei 2014 A | 35.474 | 0 | 0 | $0 |
| John Canan | Sr.V-P Finc-Global Controller | 24 Feb. 2014 A | 13.610 | 0 | 0 | $0 |
| DO CUONG V | EVP & Chief Strategy Officer | 6 Mei 2013 A | — | 0 | 0 | $0 |
| Peter S Kim | Exe V-P & Pres, MRL | 25 Feb. 2013 A | 189.609 | 0 | 0 | $0 |
| Richard S Bowles III | Exe VP&Chief Ethics & ComplOff | 10 Mei 2012 M | 73.540 | 0 | 0 | $0 |
| Chris J Scalet | Exe V-P Global Srvs & CIO | 2 Mei 2012 A | 79.829 | 0 | 0 | $0 |
| Raul E Kohan | Exe Vice President | 31 Des. 2011 F | 70.990 | 0 | 0 | $0 |
| Mervyn Turner | Chief Strategy Officer | 28 Feb. 2011 M | 26.424 | 0 | 0 | $0 |
| Richard T Clark | Chairman | 28 Feb. 2011 M | 108.211 | 0 | 0 | $0 |
| Stanley F Barshay | ExVP&PresConsHlthCare | 5 Maret 2010 M | 71.589 | 0 | 0 | $0 |
| Lori A. Queisser | Senior Vice President | 3 Nov. 2009 D | — | 0 | 0 | $0 |
| Thomas P Koestler | Executive Vice President | 3 Nov. 2009 D | 0 | 0 | 0 | $0 |
| Robert J Bertolini | Executive Vice President | 3 Nov. 2009 D | 0 | 0 | 0 | $0 |
| Brent L Saunders | Senior Vice President | 3 Nov. 2009 D | — | 0 | 0 | $0 |
| Ron C Cheeley | Senior Vice President | 3 Nov. 2009 D | 0 | 0 | 0 | $0 |
| Steven H Koehler | Vice President and Controller | 3 Nov. 2009 D | 0 | 0 | 0 | $0 |
| Thomas J Sabatino JR | Executive Vice President | 3 Nov. 2009 D | 0 | 0 | 0 | $0 |
| COX CARRIE SMITH | Executive Vice President | 3 Nov. 2009 D | 0 | 0 | 0 | $0 |
| Cecil B Pickett | Vice President | 1 Sep. 2006 | — | 0 | 0 | $0 |
| Douglas F Gingerella | Vice President and Controller | 20 Maret 2006 | — | 0 | 0 | $0 |
| Joseph C Connors | Executive Vice President | 8 Maret 2004 G | 165.410 | 0 | 0 | $0 |
| Richard W Zahn | Vice President | 1 Des. 2003 M | 33.935 | 0 | 0 | $0 |
| John P Ryan | Senior Vice President | 1 Des. 2003 M | 52.923 | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Aktivis & pemilik 5%+ 2 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| MERCK & CO., INC., MERCK SHARP & DOHME CORP., PANAMA MERGER SUB, INC. ×5 pengajuan | 4 Maret 2021 | — | Pengajuan awal | M&A / penjualan | SEC |
| Merck Global Health Innovation Fund, LLC, Merck Sharp & Dohme Corp., Merck & Co., Inc. ×2 pengajuan | 11 Mei 2016 | — | Pengajuan awal | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Kepemilikan ETF Dimiliki oleh 337 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| FTXH · First Trust Exchange-Traded Fund VI | 7,07% | 19.942 NS | 30 Juni 2026 | N-PORT |
| DJD · Invesco Exchange-Traded Fund Trust | 6,69% | 226.187 SH | 21 Agu 2026 | Harian |
| GDOC · Goldman Sachs ETF Trust | 5,94% | 10.073 NS | 31 Mei 2026 | N-PORT |
| IYH · iShares Trust | 5,69% | 1.475.784 SH | 21 Agu 2026 | Harian |
| PJP · Invesco Exchange-Traded Fund Trust | 5,45% | 193.459 SH | 21 Agu 2026 | Harian |
| FLAG · Global X Funds | 5,03% | 760 NS | 30 April 2026 | N-PORT |
| IHE · iShares Trust | 4,94% | 571.446 SH | 21 Agu 2026 | Harian |
| DOGG · First Trust Exchange-Traded Fund IV | 4,89% | 29.384 NS | 30 April 2026 | N-PORT |
| PAWZ · ProShares Trust | 4,84% | 13.228 NS | 31 Mei 2026 | N-PORT |
| IXJ · iShares Trust | 4,70% | 1.366.481 SH | 21 Agu 2026 | Harian |
| VHT · VANGUARD WORLD FUND | 4,68% | 7.432.227 SH | 19 Agu 2026 | Harian |
| TECB · iShares Trust | 4,65% | 153.076 SH | 21 Agu 2026 | Harian |
| HDV · iShares Trust | 4,41% | 4.538.992 SH | 21 Agu 2026 | Harian |
| FHLC · FIDELITY COVINGTON TRUST | 4,38% | 1.144.186 NS | 30 April 2026 | N-PORT |
| HRTS · Tema ETF Trust | 4,27% | 18.672 NS | 31 Mei 2026 | N-PORT |
| RXL · ProShares Trust | 4,26% | 25.881 NS | 31 Mei 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 4,21% | 4.289 NS | 30 April 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 3,91% | 49.491 NS | 30 April 2026 | N-PORT |
| SCHD · SCHWAB STRATEGIC TRUST | 3,86% | 30.860.833 NS | 31 Mei 2026 | N-PORT |
| PWV · Invesco Exchange-Traded Fund Trust | 3,78% | 470.038 SH | 21 Agu 2026 | Harian |
| TBG · EA Series Trust | 3,74% | 78.875 NS | 30 April 2026 | N-PORT |
| IDNA · iShares Trust | 3,68% | 60.665 SH | 21 Agu 2026 | Harian |
| CANC · Tema ETF Trust | 3,57% | 52.978 NS | 31 Mei 2026 | N-PORT |
| EDOW · First Trust Exchange-Traded Fund | 3,51% | 83.689 NS | 30 Juni 2026 | N-PORT |
| GEND · Spinnaker ETF Series | 3,11% | 1.275 NS | 30 April 2026 | N-PORT |
| AGNG · Global X Funds | 2,99% | 20.617 NS | 31 Mei 2026 | N-PORT |
| OUSA · ALPS ETF Trust | 2,95% | 184.861 NS | 31 Mei 2026 | N-PORT |
| VLLU · Harbor ETF Trust | 2,92% | 1.165 NS | 30 April 2026 | N-PORT |
| GMOV · GMO ETF Trust | 2,73% | 20.939 NS | 31 Mei 2026 | N-PORT |
| ICAP · Series Portfolios Trust | 2,68% | 24.553 NS | 31 Mei 2026 | N-PORT |
| VALQ · AMERICAN CENTURY ETF TRUST | 2,52% | 73.781 NS | 31 Mei 2026 | N-PORT |
| DDIV · First Trust Exchange-Traded Fund VI | 2,46% | 12.956 NS | 30 Juni 2026 | N-PORT |
| FTCS · First Trust Exchange-Traded Fund | 2,17% | 1.293.645 NS | 30 Juni 2026 | N-PORT |
| QDIV · Global X Funds | 2,16% | 5.965 NS | 31 Mei 2026 | N-PORT |
| DGRO · iShares Trust | 2,16% | 6.307.140 SH | 21 Agu 2026 | Harian |
| FTDS · First Trust Exchange-Traded Fund | 2,15% | 6.158 NS | 30 Juni 2026 | N-PORT |
| FBCV · FIDELITY COVINGTON TRUST | 2,14% | 31.237 NS | 30 April 2026 | N-PORT |
| NUDV · Nushares ETF Trust | 2,06% | 8.531 NS | 30 April 2026 | N-PORT |
| LOWV · AB Active ETFs, Inc. | 2,01% | 34.680 NS | 31 Mei 2026 | N-PORT |
| SNPV · DBX ETF Trust | 2,01% | 38.898 NS | 29 Mei 2026 | N-PORT |
| MEDI · Harbor ETF Trust | 2,00% | 5.048 NS | 30 April 2026 | N-PORT |
| PY · Principal Exchange-Traded Funds | 1,98% | 33.929 NS | 30 Juni 2026 | N-PORT |
| FDIV · EA Series Trust | 1,97% | 13.102 NS | 30 April 2026 | N-PORT |
| XT · iShares Trust | 1,95% | 515.140 SH | 21 Agu 2026 | Harian |
| SDOG · ALPS ETF Trust | 1,94% | 225.836 NS | 31 Mei 2026 | N-PORT |
| GCOW · Pacer Funds Trust | 1,92% | 587.741 NS | 30 April 2026 | N-PORT |
| FFLV · FIDELITY COVINGTON TRUST | 1,90% | 3.027 NS | 30 April 2026 | N-PORT |
| CCOR · Listed Funds Trust | 1,85% | 4.665 NS | 30 April 2026 | N-PORT |
| QLTY · GMO ETF Trust | 1,83% | 694.466 NS | 31 Mei 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,81% | 99.601 SH | 21 Agu 2026 | Harian |